Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

AACR 2016

16 - 20 Apr 2016
Ernest N. Morial Convention Center, New Orleans, United States of America
Entrectinib, a novel treatment for TRK fusions, shows early promise against a ra...
Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA
Entrectinib, a novel treatment for TRK fusions, shows early promise against a range of cancer types ( Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA )
6 May 2016
First outcome results from MINDACT breast cancer clinical trial
Dr Martine Piccart - Jules Bordet Institute, Brussels, Belgium
First outcome results from MINDACT breast cancer clinical trial ( Dr Martine Piccart - Jules Bordet Institute, Brussels, Belgium )
6 May 2016
Genetics may influence risk for breast cancer after chest radiotherapy to treat ...
Dr Lindsay Morton - National Cancer Institute, Bethesda, USA
Genetics may influence risk for breast cancer after chest radiotherapy to treat childhood cancer ( Dr Lindsay Morton - National Cancer Institute, Bethesda, USA )
6 May 2016
A presurgery combination therapy may improve outcomes for women with Her2-positi...
Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania, P...
A presurgery combination therapy may improve outcomes for women with Her2-positive breast cancer ( Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania, Philadelphia, USA )
6 May 2016
5 year survival rates for nivolumab-treated metastatic melanoma patients much hi...
Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA
5 year survival rates for nivolumab-treated metastatic melanoma patients much higher than historical rates ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )
6 May 2016
CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical res...
Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA
CD4 T-cell immunotherapy targeting MAGE-A3 is safe, and shows early clinical responses ( Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA )
6 May 2016
New investigational targeted therapeutic, entrectinib, shows early promise
Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA
New investigational targeted therapeutic, entrectinib, shows early promise ( Dr Alexander Drilon - Memorial Sloan Kettering Cancer Center, New York, USA )
5 May 2016
Paediatric and adult high grade gliomas: A tale of a histone tail
Dr Nada Jabado - McGill University, Montreal, Canada
Paediatric and adult high grade gliomas: A tale of a histone tail ( Dr Nada Jabado - McGill University, Montreal, Canada )
5 May 2016
Galectins in tumour immunity
Dr Gabriel Rabinovich - Instituto de Biología y Medicina Experimental, Buenos Ai...
Galectins in tumour immunity ( Dr Gabriel Rabinovich - Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina )
5 May 2016
Treatment of relapsed myeloma with novel targeted and immune therapies
Dr Kenneth Anderson - Dana–Farber Cancer Institute, Boston, USA
Treatment of relapsed myeloma with novel targeted and immune therapies ( Dr Kenneth Anderson - Dana–Farber Cancer Institute, Boston, USA )
5 May 2016
Targeting T regs in tumours
Dr Dario Vignali - University of Pittsburgh School of Medicine, Pittsburgh, USA
Targeting T regs in tumours ( Dr Dario Vignali - University of Pittsburgh School of Medicine, Pittsburgh, USA )
5 May 2016
Multiplex IHC as biomarkers for cancer immunotherapy
Dr Paul Tumeh - UCLA Medical Center, Los Angeles, USA
Multiplex IHC as biomarkers for cancer immunotherapy ( Dr Paul Tumeh - UCLA Medical Center, Los Angeles, USA )
5 May 2016
Integrating multiple omics information in the era of precision oncology
Dr Yu Shyr - Vanderbilt-Ingram Cancer Center, Nashville, USA
Integrating multiple omics information in the era of precision oncology ( Dr Yu Shyr - Vanderbilt-Ingram Cancer Center, Nashville, USA )
5 May 2016
Direct activation of STING in the tumour microenvironment leads to potent and sy...
Dr Thomas Dubensky - Aduro Biotech, Berkley, USA
Direct activation of STING in the tumour microenvironment leads to potent and systemic tumour regression and immunity ( Dr Thomas Dubensky - Aduro Biotech, Berkley, USA )
4 May 2016
Successes and challenges in designing combination immunotherapy clinical trials ...
Prof Leisha Emmens - Johns Hopkins Kimmel Cancer, Baltimore, USA
Successes and challenges in designing combination immunotherapy clinical trials for breast cancer ( Prof Leisha Emmens - Johns Hopkins Kimmel Cancer, Baltimore, USA )
4 May 2016
Breast cancer risk prediction models improved by adding multiple biological mark...
Dr Xuehong Zhang - Dana-Farber Cancer Institute, Boston, USA
Breast cancer risk prediction models improved by adding multiple biological markers of risk ( Dr Xuehong Zhang - Dana-Farber Cancer Institute, Boston, USA )
4 May 2016
Physical activity may improve prostate cancer prognosis
Dr Ying Wang - American Cancer Society, Atlanta, USA
Physical activity may improve prostate cancer prognosis ( Dr Ying Wang - American Cancer Society, Atlanta, USA )
4 May 2016
Inflammatory microenvironment regulates colorectal cancer progression
Dr Sergei Grivennikov - Fox Chase Cancer Center, Philadelphia, USA
Inflammatory microenvironment regulates colorectal cancer progression ( Dr Sergei Grivennikov - Fox Chase Cancer Center,  Philadelphia, USA )
4 May 2016
Mechanisms of immune escape in non-Hodgkin lymphoma
Dr Riccardo Dalla-Favera - Columbia University Medical Center, New York, USA
Mechanisms of immune escape in non-Hodgkin lymphoma ( Dr Riccardo Dalla-Favera - Columbia University Medical Center, New York, USA )
4 May 2016
'Helper' T Cells effective in therapy, and shows early clinical responses in pat...
Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA
'Helper' T Cells effective in therapy, and shows early clinical responses in patients with metastatic cancer ( Dr Yong-Chen William Lu - National Cancer Institute, Bethesda, USA )
4 May 2016
Innovations in assessing patient outcomes
Dr Heather Jim - Moffitt Cancer Center, Tampa, USA
Innovations in assessing patient outcomes ( Dr Heather Jim - Moffitt Cancer Center, Tampa, USA )
3 May 2016
Repopulation of cancer stem cells in therapeutic resistance
Prof Keith Chan - Baylor College of Medicine, Houston, USA
Repopulation of cancer stem cells in therapeutic resistance ( Prof Keith Chan - Baylor College of Medicine, Houston, USA )
3 May 2016
Technologies for personalised cancer immunotherapies
Prof James Heath - California Institute of Technology, Pasadena, USA
Technologies for personalised cancer immunotherapies ( Prof James Heath - California Institute of Technology, Pasadena, USA )
3 May 2016
Modulating the DNA damage response: The role of cell cycle checkpoint inhibitors
Dr Shivaani Kummar - Stanford University, Stanford, USA
Modulating the DNA damage response: The role of cell cycle checkpoint inhibitors ( Dr Shivaani Kummar - Stanford University, Stanford, USA )
3 May 2016
Multi-target S-DNA increases colorectal cancer screening among previously non-co...
Dr Barry Berger - Exact Sciences, Madison, USA
Multi-target S-DNA increases colorectal cancer screening among previously non-compliant patients ( Dr Barry Berger - Exact Sciences, Madison, USA )
29 Apr 2016
p62: Metabolism and the tumour microenvironment
Prof Jorge Moscat - Sanford Burnahm Prebys Medical Discovery Institute, La Jolla...
p62: Metabolism and the tumour microenvironment ( Prof Jorge Moscat - Sanford Burnahm Prebys Medical Discovery Institute, La Jolla, USA )
29 Apr 2016
Cancer cells plasticity and drug resistance
Dr Rafaella Sordella - Cold Harbor Spring Laboratory, New York, USA
Cancer cells plasticity and drug resistance ( Dr Rafaella Sordella - Cold Harbor Spring Laboratory, New York, USA )
29 Apr 2016
Targeted therapy shows continued promise in patients whose tumours had NTRK gene...
Dr David Hong - University of Texas MD Anderson Cancer Center, Houston, USA
Targeted therapy shows continued promise in patients whose tumours had NTRK gene fusions ( Dr David Hong - University of Texas MD Anderson Cancer Center, Houston, USA )
29 Apr 2016
Drugging “undruggable” transcription factor drivers in cancer
Dr John Bushweller - Unviersity of Virgina, Virginia, USA
Drugging “undruggable” transcription factor drivers in cancer ( Dr John Bushweller - Unviersity of Virgina, Virginia, USA )
28 Apr 2016
Pembrolizumab yielded durable responses in patients with advanced Merkel cell ca...
Dr Paul Nghiem - University of Washington, Seattle, USA
Pembrolizumab yielded durable responses in patients with advanced Merkel cell carcinoma ( Dr Paul Nghiem - University of Washington, Seattle, USA )
28 Apr 2016
Combination therapy before surgery improves outcomes for patients with HER2 posi...
Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania, P...
Combination therapy before surgery improves outcomes for patients with HER2 positive breast cancer ( Dr Angela DeMichele - Perelmen School of Medicine, University of Pennsylvania, Philadelphia, USA )
28 Apr 2016
Elucidation and pharmacological targeting of tumour checkpoint dependencies
Dr Andrea Califano - Colombia University Medical Centre, New York, USA
Elucidation and pharmacological targeting of tumour checkpoint dependencies ( Dr Andrea Califano - Colombia University Medical Centre, New York, USA )
28 Apr 2016
Identifying myeloid-driven biologies
Dr Brian Ruffell - Moffitt Cancer Center, Tampa, USA
Identifying myeloid-driven biologies ( Dr Brian Ruffell - Moffitt Cancer Center, Tampa, USA )
28 Apr 2016
Metastasis intiation mediated by thrombospondin 2
Dr Ilaria Malanchi - Crick Institute, London, UK
Metastasis intiation mediated by thrombospondin 2 ( Dr Ilaria Malanchi - Crick Institute, London, UK )
27 Apr 2016
New technology can potentially overcome CAR T-cell limitations
Dr Philip Low - Purdue University, West Lafayette, USA
New technology can potentially overcome CAR T-cell limitations ( Dr Philip Low - Purdue University, West Lafayette, USA )
27 Apr 2016
Cell of origin role in cancer stem cell and GBM phenotype
Dr Luis Parada - Memorial Sloan Kettering Cancer Centre, New York, USA
Cell of origin role in cancer stem cell and GBM phenotype ( Dr Luis Parada - Memorial Sloan Kettering Cancer Centre, New York, USA )
27 Apr 2016
New RAF-targeted therapeutic shows early promise against tumours with BRAF and R...
Dr Jayesh Desai - Royal Melbourne Hospital, Melbourne, Australia
New RAF-targeted therapeutic shows early promise against tumours with BRAF and RAS mutations ( Dr Jayesh Desai - Royal Melbourne Hospital, Melbourne, Australia )
27 Apr 2016
MINDACT breast cancer clinical trial: First results and impact on future trial d...
Dr Martine Piccart - Jules Bordet Institute, Brussels, Belgium
MINDACT breast cancer clinical trial: First results and impact on future trial design ( Dr Martine Piccart - Jules Bordet Institute, Brussels, Belgium )
27 Apr 2016
Breast cancer research news from AACR President Nancy Davidson
Dr Nancy Davidson - AACR President, Philadelphia, USA
Breast cancer research news from AACR President Nancy Davidson ( Dr Nancy Davidson - AACR President, Philadelphia, USA )
27 Apr 2016
Non-coding mutations driving chronic lymphocytic leukaemia
Dr Xose Puente - University of Oviedo, Oviedo, Spain
Non-coding mutations driving chronic lymphocytic leukaemia ( Dr Xose Puente - University of Oviedo, Oviedo, Spain )
27 Apr 2016
SPF30 sunscreens delay melanoma incidence in preclinical model
Dr Christin Burd - Ohio State University, Columbus, USA
SPF30 sunscreens delay melanoma incidence in preclinical model ( Dr Christin Burd - Ohio State University, Columbus, USA )
26 Apr 2016
Comparison of three different PD-L1 diagnostic tests shows a high degree of conc...
Dr Marianne Ratcliffe - AstraZeneca, UK
Comparison of three different PD-L1 diagnostic tests shows a high degree of concordance ( Dr Marianne Ratcliffe - AstraZeneca, UK )
26 Apr 2016
Next-generation sequencing in the lymphoid malignancies
Dr Aaron Logan - UCSF, San Fransisco, USA
Next-generation sequencing in the lymphoid malignancies ( Dr Aaron Logan - UCSF, San Fransisco, USA )
26 Apr 2016
Mutational clonality and intratumour heterogeneity as biomarkers for cancer immu...
Dr Nicholas McGranahan - Crick Institute, London, UK
Mutational clonality and intratumour heterogeneity as biomarkers for cancer immunotherapy ( Dr Nicholas McGranahan - Crick Institute, London, UK )
26 Apr 2016
Risk of breast cancer after chest radiotherapy may be affected by genetics
Dr Lindsay Morton - National Cancer Institute, Bethesda, USA
Risk of breast cancer after chest radiotherapy may be affected by genetics ( Dr Lindsay Morton - National Cancer Institute, Bethesda, USA )
26 Apr 2016
Retroviral replicating vectors for cancer-targeted gene therapy and immunotherap...
Dr Noriyuki Kasahara - Miami University School of Medicine, Miami, USA
Retroviral replicating vectors for cancer-targeted gene therapy and immunotherapy ( Dr Noriyuki Kasahara - Miami University School of Medicine, Miami, USA )
26 Apr 2016
Imaging tumour habitats - life at the edge
Robert Gillies - Moffitt Cancer Center, Tampa, USA
Imaging tumour habitats - life at the edge ( Robert Gillies - Moffitt Cancer Center, Tampa, USA )
26 Apr 2016
NY-ESO-1 immunotherapy for ovarian cancer
Dr Kunle Odunsi - Roswell Park Cancer Institute, Buffalo, USA
NY-ESO-1 immunotherapy for ovarian cancer ( Dr Kunle Odunsi - Roswell Park Cancer Institute, Buffalo, USA )
26 Apr 2016
Normal and neoplastic stem cells
Prof Irving L Weissman - Stanford University School of Medicine, Stanford, USA
Normal and neoplastic stem cells ( Prof Irving L Weissman - Stanford University School of Medicine, Stanford, USA )
26 Apr 2016